Retatrutide Is Now the Most-Tracked Compound of 2026
This is anonymized, aggregated tracking data from thousands of Regimen users, with percentages rounded to the nearest 5%. It reflects what people track, not what any compound does, and it is not medical advice or an endorsement of anything.
Updated July 2026. A quick read on what the Regimen dataset actually shows about which compounds people are logging in 2026, and how they're combining them.
The most-tracked compounds of 2026
| Compound | Share of people tracking it |
|---|---|
| Retatrutide | ~50% |
| Testosterone cypionate | ~15% |
| GHK-Cu | ~15% |
| Tirzepatide | ~15% |
| MOTS-c | ~10% |
| NAD+ | ~10% |
| Tesamorelin | ~10% |
| BPC-157 | ~10% |
That's the number that caught even us off guard. Retatrutide is a next-generation triple agonist still working through trials, so it isn't FDA-approved yet, and it's already outrunning every name people have been taking for years. Folks are clearly tracking what's coming, not just what's already on the shelf. Background on the compound and where it stands: retatrutide vs tirzepatide and what's next after retatrutide.
People run stacks, not single compounds
- The average person tracks around three compounds at once.
- Roughly 35% run two or more at the same time.
- About a quarter run a GLP-1 and a peptide together.
The person on a GLP-1 for weight is also running a peptide for recovery, with testosterone underneath it. The tidy lanes (weight-loss drug vs TRT vs peptides) don't match how people actually live anymore. That's exactly why tracking stopped being optional: three compounds on three schedules is more than memory and a notes app can hold. See the multi-compound protocol tracking guide for the patterns that show up most.
Track every compound, dose, and site with Regimen
- Smart reminders so you never miss a dose
- Progress tracking with photos and weight
- Medication level curves for every compound
Method
Aggregate share of Regimen users tracking each compound as of July 2026, computed from anonymized production data, expressed as the rounded share of people who log each compound. Percentages are rounded to the nearest 5% and can sum above 100% because most users track more than one compound. No individual data, no identifying information, no geographic precision finer than country.
Frequently asked questions
What's the most-tracked compound in 2026?
Retatrutide, logged by about half the people tracking a protocol on Regimen, ahead of every GLP-1, peptide, and testosterone ester.
Is retatrutide FDA-approved?
No. It's an investigational triple agonist still in clinical trials as of 2026.
How many compounds does the average person track?
Around three, and about a third run two or more at once.
How was this measured?
Anonymized, aggregated tracking data from thousands of Regimen users, expressed as the rounded share of people who log each compound.
This reflects tracking behavior only. Not medical advice, not an endorsement. Several compounds referenced are investigational or research-only; anything you run should be legally obtained and ideally supervised by a clinician.
Ready to track your protocol?
- Smart reminders so you never miss a dose
- Track weight, photos, and progress over time
- Medication level curves for every compound